United States (USA) (US)

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Operando methods: A new era of electrochemistry (2023) Yang Y, Feijóo J, Briega-Martos V, Li Q, Krumov M, Merkens S, De Salvo G, et al. Journal article, Review article Thermal performance and corrosion resistance analysis of inorganic eutectic phase change material with one dimensional carbon nanomaterial (2023) Kalidasan B, Pandey AK, Saidur R, Mishra YN, Ma Z, Tyagi VV Journal article Digital staining in optical microscopy using deep learning - a review (2023) Kreiss L, Jiang S, Li X, Xu S, Zhou KC, Lee KC, Mühlberg A, et al. Journal article, Review article Sensory spinal interoceptive pathways and energy balance regulation (2023) Münzberg H, Berthoud HR, Neuhuber W Journal article, Review article Potential of the Julia Programming Language for High Energy Physics Computing (2023) Eschle J, Gál T, Giordano M, Gras P, Hegner B, Heinrich L, Hernandez Acosta U, et al. Journal article Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study (2023) Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. Journal article Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial) (2023) Breyer J, Eckstein M, Sikic D, Wezel F, Roghmann F, Brehmer M, Wirtz RM, et al. Journal article PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation (2023) Linnerbauer M, Beyer T, Nirschl L, Farrenkopf D, Lößlein L, Vandrey O, Peter A, et al. Journal article Shared metadata for data-centric materials science (2023) Ghiringhelli LM, Baldauf C, Bereau T, Brockhauser S, Carbogno C, Chamanara J, Cozzini S, et al. Journal article Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant (2023) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Journal article